Ieq Capital LLC Takes $596,000 Position in Keros Therapeutics, Inc. $KROS

Ieq Capital LLC purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 55,675 shares of the company’s stock, valued at approximately $596,000. Ieq Capital LLC owned approximately 0.28% of Keros Therapeutics as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. BlackRock Inc. bought a new position in Keros Therapeutics in the second quarter valued at about $29,898,000. Deutsche Bank AG bought a new position in shares of Keros Therapeutics in the second quarter worth about $501,000. Bank of New York Mellon Corp bought a new position in shares of Keros Therapeutics in the second quarter worth about $1,106,000. ADAR1 Capital Management LLC lifted its holdings in shares of Keros Therapeutics by 416.2% in the first quarter. ADAR1 Capital Management LLC now owns 97,318 shares of the company’s stock worth $1,074,000 after acquiring an additional 78,467 shares during the last quarter. Finally, Empowered Funds LLC boosted its stake in shares of Keros Therapeutics by 142.2% in the 1st quarter. Empowered Funds LLC now owns 145,517 shares of the company’s stock valued at $1,607,000 after purchasing an additional 85,439 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on KROS. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Leerink Partners dropped their target price on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. Zacks Research lowered Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Finally, Wall Street Zen raised Keros Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 24th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $20.50.

Keros Therapeutics Stock Down 1.8%

NASDAQ KROS opened at $11.03 on Friday. The company has a market capitalization of $218.72 million, a price-to-earnings ratio of -2.98 and a beta of 0.99. Keros Therapeutics, Inc. has a twelve month low of $9.69 and a twelve month high of $22.55. The stock has a fifty day simple moving average of $10.78 and a 200 day simple moving average of $11.61.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Research analysts expect that Keros Therapeutics, Inc. will post -5.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the transaction, the insider owned 27,559 shares in the company, valued at approximately $283,582.11. This trade represents a 11.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Nima Farzan sold 2,625 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the transaction, the director owned 9,767 shares in the company, valued at $104,799.91. This trade represents a 21.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,768 shares of company stock valued at $144,979. Insiders own 12.60% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.